#ACC21: No­var­tis' En­tresto takes its 2nd fail­ure of the week­end at ACC, show­ing no ben­e­fit in most dire heart fail­ure pa­tients

No­var­tis’ En­tresto start­ed the ACC week­end off rough with a tri­al flop in heart at­tack pa­tients, slow­ing the drug’s push in­to ear­li­er pa­tients. Now, an NIH-spon­sored study is cast­ing doubt on En­tresto’s use in the most se­vere heart fail­ure pa­tients, an­oth­er black mark on the in­creas­ing­ly con­tro­ver­sial drug’s record.

En­tresto, a com­bi­na­tion of sacu­bi­tril and val­sar­tan, could not beat out val­sar­tan alone in an out­comes head-to-head for se­vere heart fail­ure pa­tients with a re­duced ejec­tion frac­tion (HFrEF), ac­cord­ing to da­ta pre­sent­ed Mon­day at the vir­tu­al Amer­i­can Col­lege of Car­di­ol­o­gy meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER